Handelsbanken Fonder AB lifted its stake in Celgene Corporation (NASDAQ:CELG) by 9.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 486,449 shares of the biopharmaceutical company’s stock after purchasing an additional 42,000 shares during the period. Celgene Corporation makes up 1.6% of Handelsbanken Fonder AB’s investment portfolio, making the stock its 19th largest holding. Handelsbanken Fonder AB owned 0.06% of Celgene Corporation worth $63,175,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. State Street Corp lifted its stake in shares of Celgene Corporation by 2.3% in the first quarter. State Street Corp now owns 32,473,417 shares of the biopharmaceutical company’s stock valued at $4,040,668,000 after purchasing an additional 723,844 shares during the period. Bank of New York Mellon Corp lifted its stake in shares of Celgene Corporation by 4.9% in the first quarter. Bank of New York Mellon Corp now owns 10,088,473 shares of the biopharmaceutical company’s stock valued at $1,255,309,000 after purchasing an additional 472,067 shares during the period. American Century Companies Inc. lifted its stake in shares of Celgene Corporation by 4.4% in the first quarter. American Century Companies Inc. now owns 6,563,791 shares of the biopharmaceutical company’s stock valued at $816,733,000 after purchasing an additional 276,089 shares during the period. Pioneer Investment Management Inc. lifted its stake in shares of Celgene Corporation by 15.7% in the first quarter. Pioneer Investment Management Inc. now owns 5,231,139 shares of the biopharmaceutical company’s stock valued at $650,911,000 after purchasing an additional 710,584 shares during the period. Finally, Clearbridge Investments LLC lifted its stake in shares of Celgene Corporation by 24.1% in the first quarter. Clearbridge Investments LLC now owns 4,601,919 shares of the biopharmaceutical company’s stock valued at $572,617,000 after purchasing an additional 892,392 shares during the period. Hedge funds and other institutional investors own 79.43% of the company’s stock.

Celgene Corporation (NASDAQ:CELG) traded down 0.01% during midday trading on Thursday, reaching $141.25. 1,197,337 shares of the company’s stock traded hands. Celgene Corporation has a 52 week low of $96.93 and a 52 week high of $142.64. The stock has a market capitalization of $110.51 billion, a price-to-earnings ratio of 43.74 and a beta of 1.89. The company’s 50-day moving average price is $134.52 and its 200 day moving average price is $127.11.

Celgene Corporation (NASDAQ:CELG) last posted its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.61 by $0.21. The business had revenue of $3.27 billion during the quarter, compared to analyst estimates of $3.23 billion. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. The firm’s revenue was up 18.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.44 earnings per share. On average, equities research analysts expect that Celgene Corporation will post $7.32 earnings per share for the current year.

In other news, Director Michael D. Casey sold 9,250 shares of the stock in a transaction that occurred on Monday, June 19th. The shares were sold at an average price of $125.59, for a total value of $1,161,707.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Robert J. Hugin sold 175,970 shares of the stock in a transaction that occurred on Thursday, June 22nd. The stock was sold at an average price of $134.14, for a total transaction of $23,604,615.80. Following the completion of the sale, the insider now directly owns 1,033,909 shares of the company’s stock, valued at $138,688,553.26. The disclosure for this sale can be found here. Insiders sold 258,226 shares of company stock valued at $34,503,411 over the last three months. 0.95% of the stock is owned by insiders.

ILLEGAL ACTIVITY WARNING: This piece of content was originally published by Daily Political and is owned by of Daily Political. If you are viewing this piece of content on another publication, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2017/09/14/handelsbanken-fonder-ab-has-63-18-million-stake-in-celgene-corporation-celg.html.

Several analysts recently commented on CELG shares. Oppenheimer Holdings, Inc. set a $148.00 price objective on shares of Celgene Corporation and gave the company a “buy” rating in a research note on Thursday, June 8th. Cann reiterated a “buy” rating on shares of Celgene Corporation in a research note on Wednesday, June 7th. Canaccord Genuity set a $156.00 price objective on shares of Celgene Corporation and gave the company a “buy” rating in a research note on Tuesday, June 6th. Mizuho raised their price objective on shares of Celgene Corporation from $130.00 to $134.00 and gave the company a “buy” rating in a research note on Thursday, June 1st. Finally, BTIG Research reiterated a “buy” rating and issued a $138.00 price objective on shares of Celgene Corporation in a research note on Wednesday, May 24th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and twenty-two have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $147.31.

About Celgene Corporation

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.